Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481X |
| Therapy | Ibrutinib |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481X | chronic lymphocytic leukemia | predicted - resistant | Ibrutinib | Phase II | Actionable | In a Phase II trial, BTK C481X and/or PLCG2 mutations were identified in 80% (8/10) of patients with progressive disease and in 20% (1/5) of patients with prolymphocytic transformation of chronic lymphocytic leukemia while on Imbruvica (ibrutinib) treatment (PMID: 28049639, NCT01500733). | 28049639 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28049639) | Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. | Full reference... |